Carboxamide derivatives as therapeutic agents
View Patent ↗This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
1. A method for treating Alzheimer's disease by inhibiting a Receptor for Advanced Glycated Endproducts (RAGE) which comprises administering to a subject in need thereof a therapeutically effective amount of at least one RAGE inhibitor compound of Formula (I)
wherein
G 1 is (CH 2 ) k , where k is 1 to 3;
G 2 is
a) hydrogen
b) —C 1-6 alkyl;
c) -aryl;
d) —C 1-6 alkylaryl;
where R 5 and R 6 are independently selected from the group consisting of
i) —H;
ii) —C 1-6 alkyl;
iii) -aryl;
iv) —C 1-6 alkylaryl;
v) —C(O)—O—C 1-6 alkyl;
vi) —C(O)—O—C 1-6 alkylaryl;
vii) —C(O)—O—C 1-6 alkylcycloalkylaryl;
viii) —C(O)—NH—C 1-6 alkyl;
ix) —C(O)—NH—C 1-6 alkylaryl;
x) —SO 2 —C 1-6 alkyl;
xi) —SO 2 —C 1-6 alkylaryl;
xii) —SO 2 -aryl;
xiii) —SO 2 —NH—C 1-6 alkyl;
xiv) —SO 2 —NH—C 1-6 alkylaryl;
xvi) —C(O)—C 1-6 alkyl; and
xvii) —C(O)—C 1-6 alkylaryl; or
f) a group of the formula
wherein
R 9 , R 10 , and R 11 are independently selected from the group consisting of
i) -hydrogen;
ii) —C 1-6 alkyl;
iii) -aryl;
iv) —C 1-6 alkylaryl;
v) —C(O)—O—C 1-6 alkyl;
vi) —C(O)—O—C 1-6 alkylaryl;
vii) —C(O)—NH—C 1-6 alkyl;
viii) —C(O)—NH—C 1-6 alkylaryl;
ix) —SO 2 —C 1-6 alkyl;
x) —SO 2 —C 1-6 alkylaryl;
xi) —SO 2 -aryl;
xii) —SO 2 —NH—C 1-6 alkyl;
xiii) —SO 2 —NH—C 1-6 alkylaryl;
xiv) —C(O)—C 1-6 alkyl; and
xv) —C(O)—C 1-6 alkylaryl; or
R 10 and R 11 are taken together to constitute a fused cycloalkyl, fused heterocyclyl, or fused aryl ring containing the atoms to which R 10 and R 11 are bonded;
R 1 is
a) hydrogen;
b) —C 1-6 alkyl;
c) -aryl; or
d) —C 1-6 alkylaryl;
R 2 is
a) —C 1-6 alkyl;
b) -aryl;
c) —C 1-6 alkylaryl; or
d) a group of the formula
wherein m and n are independently selected from 1, 2, 3, or 4; X is a direct bond, CH 2 —, —O—, —S—, —S(O 2 )—, —C(O)—, —CON(H)—, —NHC(O)—, —NHCON(H)—, —NHSO 2 —, —SO 2 N(H)—, —C(O)—O—, —O—C(O)—, —NHSO 2 NH—,
-Q 1 - is C 1-6 alkylene, C 2-6 alkenylene, or C 2-6 alkynylene;
R 3 is
a) hydrogen;
b) —C 1-6 alkyl;
c) —C 1-6 alkylaryl; or
d) —C 1-6 alkoxyaryl;
wherein L is —CH 2 —, —O—, —N(H)—, —S—, SO 2 —, —CON(H)—, —NHC(O)—, —NHCON(H)—, —NHSO 2 —, —SO 2 N(H)—, —C(O)—O—, —NHSO 2 NH—, —O—CO—,
R 36 and R 37 are independently selected from the group consisting of hydrogen, aryl, C 1 -C 6 alkyl, C 1 -C 6 alkylaryl, C 1 -C 6 alkoxy, and C 1 -C 6 alkoxyaryl
R 12 and R 13 are independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkylaryl, and aryl;
R 7 and R 8 are independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkylaryl, and aryl; or R 7 and R 8 are taken together to form a ring having the formula —(CH 2 ) o′ —Z′—(CH 2 ) p′ — bonded to the atoms to which R 7 and R 8 are attached, wherein o′ and p′ are, independently, 1, 2, 3, or 4; Z′ is a direct bond, —CH 2 —, —O—, —S—, —S(O 2 )—, —C(O)—, —CON(H)—, —NHC(O)—, —NHCON(H)—, —NHSO 2 —; —SO 2 N(H)—, —C(O)—O—, —O—C(O)—, —NHSO 2 NH—,
R 40 and R 41 are independently selected from the group consisting of hydrogen, aryl, C 1 -C 6 alkyl, and C 1 -C 6 alkylaryl; and
wherein
the aryl and/or alkyl group(s) in R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , and R 13 may be optionally substituted 1-4 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups:
a) —H;
b) —Y—C 1-6 alkyl;
—Y-aryl;
—Y—C- 1-6 alkylaryl;
—Y—C 1-6 - alkyl-NR 14 R 15 ;
—Y—C 1-6 -alkyl-W—R 16 ;
wherein Y and W are independently selected from the group consisting of —CH 2 —, —O—, —N(H), —S—, SO 2 —, —CON(H)—, —NHC(O)—, —NHCON(H)—, —NHSO 2 —, —SO 2 N(H)—, —C(O)—O—, —NHSO 2 NH—, —O—CO—,
R 16 , R 17 , and R 18 are independently selected from the group consisting of hydrogen, aryl, C 1 -C 6 alkyl, C 1 -C 6 alkylaryl, C 1 -C 6 alkoxy, and C 1 -C 6 alkoxyaryl; and
c) halogen, hydroxyl, cyano, carbamoyl, and carboxyl; and
R 14 and R 15 are independently selected from the group consisting of hydrogen, aryl, C 1 -C 6 alkyl, and C 1 -C 6 alkylaryl; or
R 14 and R 15 are taken together to form a ring having the formula —(CH 2 ) o —Z—(CH 2 ) p — bonded to the nitrogen atom to which R 14 and R 15 are attached, wherein o and p are, independently, 1, 2, 3, or 4; Z is a direct bond, —CH 2 —, —O—, —S—, —S(O 2 )—, —C(O)—, —CON(H)—, —NHC(O)—, —NHCON(H)—, —NHSO 2 —, —SO 2 N(H)—, —C(O)—O—, —O—C(O)—, —NHSO 2 NH—,
R 19 and R 20 are independently selected from the group consisting of hydrogen, aryl, C 1 -C 6 alkyl, and C 1 -C 6 alkylaryl,
or a pharmaceutically acceptable salt thereof, wherein a therapeutically effective amount comprises sufficient RAGE inhibitor compound to at least partially inhibit the binding of a ligand to the RAGE.
2. The method of claim 1 , wherein the RAGE inhibitor compound is mixed with a pharmaceutical carrier.
3. The method of claim 1 , wherein the RAGE inhibitor compound is administered parenterally, orally, topically, rectally or by inhalation as a spray.
4. The method of claim 1 , wherein the RAGE inhibitor compound comprises a dosage ranging from 0.01 to 500 mg/kg/day.
5. The method of claim 1 , wherein the RAGE inhibitor compound comprises a dosage ranging from 0.01 to 200 mg/kg/day.
6. The method of claim 1 , wherein the RAGE inhibitor compound comprises a dosage ranging from 0.1 to 100 mg/kg/day.
7. The method of claim 1 , wherein the RAGE inhibitor compound comprises a unit dosage ranging from 5 to 500 mg.
8. The method of claim 1 , wherein the RAGE inhibitor compound is 3-(3-Tert-butoxyphenyl)-3-(9-fluorenylmethoxycarbonylamino)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide or a pharmaceutically acceptable salt thereof.
9. The method of claim 1 , wherein the RAGE inhibitor compound is 3-(3-Tert-butoxyphenyl)-3-aminopropionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide or a pharmaceutically acceptable salt thereof.
10. The method of claim 1 , wherein the RAGE inhibitor compound is 3-(4-Tert-butoxyphenyl)-3-(9-fluorenylmethoxycarbonylamino)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide or a pharmaceutically acceptable salt thereof.
11. The method of claim 1 , wherein the RAGE inhibitor compound is 3-amino-3-(4-tert-butoxyphenyl)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide or a pharmaceutically acceptable salt thereof.
12. The method of claim 1 , wherein the RAGE inhibitor compound is 3-(9-fluorenylmethoxycarbonylamino)-3-(2-tert-butoxyphenyl)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide or a pharmaceutically acceptable salt thereof.
13. The method of claim 1 , wherein the RAGE inhibitor compound is 3-amino-3-(2-tert-butoxyphenyl)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide or a pharmaceutically acceptable salt thereof.
14. The method of claim 1 , wherein the RAGE inhibitor compound is 3-Isopropylamino-3-(3-tert-butoxyphenyl)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide or a pharmaceutically acceptable salt thereof.